All News

Article

ACR Convergence 2025 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases

ACR Press Release Oct 26, 2025

At ACR Convergence 2025, new research explored critical disparities and epidemiologic trends shaping outcomes in autoimmune rheumatic diseases across diverse populations and age groups. Studies presented at the meeting highlighted issues ranging from kidney transplant outcomes in lupus to medication disparities in rheumatoid arthritis and demographic patterns in systemic sclerosis and axial spondyloarthritis.

Rheumatologists love AI scribes in clinic. The way we interact is potentially well suited, and accuracy and synthesis quality is bound to improve. Is it inevitable that it will universally be standard practice for us soon? UCSF clinics #ACR25 @JYazdanyMD ABST0189 @RheumNow https://t.co/kOzfpLlvgD

https://x.com/drdavidliew/status/1982539272386478293/photo/1

#0793 In #SLE, abusive trauma was linked to 58% higher risk of medication non-adherence; resilience buffered this effect. Patients with trauma cited motivational, not access-related, barriers. Trauma-informed & resilience-focused care may improve adherence. @RheumNow #ACR25

#0794 LLMs can accelerate qualitative lupus pregnancy research. Using AI to translate & analyze interviews from Portuguese, GPT-4 achieved top accuracy & coherence vs human themes. LLMs may expand inclusion & equity in rheum research. @RheumNow #ACR25 https://t.co/TAxg6Qyk0L

https://x.com/DrMiniDey/status/1982528657613640150/photo/1

RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

What is #nonadherence in #SLE associated with? 115 Pts w #lupus in Spain Overall medication adherence 58%! 👇Reduced if Male Low education No partner -NS adjusted analysis Unemployed Comorbidities 3 or more drugs/pills -NS adjusted #ACR25 @RheumNow @ACRheum #abst0216 https://t.co/CkG6gpiCw3

https://x.com/Janetbirdope/status/1982521250959565160/photo/1

Two Jacks, One mission 🤓 Head on to the booth and get a chance to meet either one of them (both if you’re lucky, like me!) Continue tuning in for coverage of #ACR25 by the @RheumNow faculty and KOLs https://t.co/Y2pS8CpoH5

https://x.com/RHEUMarampa/status/1982518851050037697/photo/1

#0777 Big news for VEXAS! 🎯 The first validated disease activity index (VEXAS-DAI) has been developed via international Delphi consensus. A 12-domain, 40-point tool to standardise assessment & power trials in this complex syndrome. Validation underway! @RheumNow #ACR25 https://t.co/DSeHb7eNeV

https://x.com/DrMiniDey/status/1982510034925015534/photo/1

In case there was any doubt: GCA leads to ischemic vision loss PMR does not #ACR25 ABST0753 @RheumNow https://t.co/mCS9B4Flgl

https://x.com/drdavidliew/status/1982503756211310648/photo/1

Leflunomide - a perennial question in GCA, that we still haven’t answered (as this meta-analysis shows), despite clear potential. We are getting a clearer idea of the strengths/limitations of MTX in GCA, is it now time to get better clarity for LEF? #ACR25 ABST0731 @RheumNow https://t.co/ycuvPx8Xdg

https://x.com/drdavidliew/status/1982502466483855856/photo/1

Using ChatGPT to diagnose axSpA, in 10 low back pain cases, it outperformed clinicians in diagnostic precision (75% vs. 60%) and sensitivity (85% vs. 80%), completing the task 5x faster. Specialty framing (e.g., Rheum vs Neuro) didn’t affect accuracy. Abstract 0530 @RheumNow https://t.co/YMMC4XIX9m

https://x.com/synovialjoints/status/1982499970197414083/photo/1

Project from my group & rheum-bound resident Mary Peng! As expected, ischemic vision loss for GCA compared to PMR (HR 5.4) and gen pop (HR 5.6) 😬 NO difference for PMR vs gen pop (aHR 1.10, 95% CI 0.86–1.41) Reassuring for pts w/PMR! #ACR25 @RheumNow Abstr#0753 #ACRBest https://t.co/HKzc7OOzmP

https://x.com/EBRheum/status/1982494684107727105/photo/1

Cool study using vasculitis patient-powered reserach network (VPPRN) "SNOT-22" tool captures sinonasal symptoms; associated with disease activity (expected) but also worse among pts even in remission Very important impacter of QOL in AAV #ACR25 @RheumNow Abstr0725 https://t.co/NQBW8VnYFS

Miller et al. Fibrinogen for GCA diagnosis and flare identification. Similar to ESR/CRP in diagnosis. For flares, lower sensitivity (79%) but better specificity (96%) @RheumNow #ACR25 Abstr#750 https://t.co/SIkAkEeYh1

https://x.com/RichardPAConway/status/1982484365751075203/photo/1

Poster evaluating representation in trials of AAV and GCA Results mirror those observed in other fields; need to keep advocating for trials in all populations! #ACR25 @RheumNow Abstr#0720 https://t.co/gDj5IQMJOc

https://x.com/EBRheum/status/1982485372568482227/photo/1

In a novel Geri-Rheum clinic, cognitive screening revealed 35% impairment among adults >55 yrs. Common deficits: visuospatial, attention & recall. Early geriatric screening = earlier intervention. A model for age-friendly rheum care in action. @RheumNow #ACR25 Abstract #0226 https://t.co/lIAcrZvL4H

https://x.com/JihaRheum/status/1982482353097224699/photo/1

#ACR25 Abstr#775 Previous study showed plasma tRNA-derived RNA (tDR-1), produced by bacteria from the phylum Proteobacteria, was assoc. with lower RA activity. In 60 At-Risk CCP3+ people, Plasma tDR-1 improved prediction of RA. Need validation & adoption in practice @RheumNow https://t.co/XBmtohBEHc

https://x.com/Yuz6Yusof/status/1982477761924272617/photo/1

From the FOREMOST study factors predicting progression from oligo to polyarticular PsA: Female sex, enthesitis and dactylitis found to increase the risk of progression. Among patients in FOREMOST receiving PBO, prior csDMARD use was protective. Abstract#0576 @RheumNow #ACR25 https://t.co/CFMhAFgFBa

https://x.com/synovialjoints/status/1982477323505906048/photo/1

#0191 We found that in a large South London RA cohort, use of advanced therapy in moderate disease (DAS28 3.2-5.1) generally followed NICE guidance. Gaps often reflected telehealth limiting DAS assessment and patient hesitancy. Self-assessment tools may help. @RheumNow #ACR25 https://t.co/UMGtkfABHn

https://x.com/DrMiniDey/status/1982477322843472089/photo/1

RheumNow’s expanded coverage of the #ACR2025 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.

Topics

All News

ACR Convergence 2025 Sheds Light on Disparities, Age-Related Trends, and Epidemiology in Autoimmune Rheumatic Diseases

Do you get our email newsletter?